3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans
Authors:
Abstract
(±)3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”), a ring‐substituted amphetamine derivative first synthesized in 1914, has emerged as a popular recreational drug of abuse over the last decade. Pharmacological studies indicate that MDMA produces a mixture of central stimulant and psychedelic effects, many of which appear to be mediated by brain monoamines, particularly serotonin and dopamine. In addition to its pharmacologic actions, MDMA has been found to possess toxic activity toward brain serotonin neurones. Serotonergic neurotoxicity after MDMA has been demonstrated in a variety of experimental animals (including non‐human primates). In monkeys, the neurotoxic dose of MDMA closely approaches that used by humans. While the possibility that MDMA is also neurotoxic in humans is under investigation, other adverse effects of MDMA in humans have been documented, including various systemic complications and a number of untoward neuropsychiatric sequelae. Notably, many of the adverse neuropsychiatric consequences noted after MDMA involve behavioral domains putatively influenced by brain serotonin (e.g., mood, cognition and anxiety). Given the restricted status of MDMA use, retrospective clinical observations from suspecting clinicians will probably continue to be a primary source of information regarding MDMA's effects in humans. As such, this article is intended to familiarize the reader with the behavioral pharmacology and toxicology of MDMA, with the hope that improved recognition of MDMA‐related syndromes will provide insight into the function of serotonin in the human brain, in health as well as disease.Keywords
This publication has 91 references indexed in Scilit:
- Enzymic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomesChemical Research in Toxicology, 1992
- Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl]propane [(methylenedioxy)methamphetamine]Chemical Research in Toxicology, 1992
- Psychiatric illness associated with "ecstasy"The Lancet, 1991
- ‘Ecstasy’ Psychosis and FlashbacksThe British Journal of Psychiatry, 1991
- Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the ratPharmacology Biochemistry and Behavior, 1991
- Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by microdialysisLife Sciences, 1990
- Stereochemistry of the metabolism of MDMA to MDALife Sciences, 1989
- Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administrationBrain Research, 1988
- Incidence of Recreational Use of 3,4-Methylenedimethoxymethamphetamine (MDMA, Ecstasy) on an Undergraduate CampusNew England Journal of Medicine, 1987
- Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the ratFundamental and Applied Toxicology, 1987